Li‐Tzong Chen

17.4k total citations · 3 hit papers
296 papers, 7.3k citations indexed

About

Li‐Tzong Chen is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Li‐Tzong Chen has authored 296 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Oncology, 105 papers in Surgery and 84 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Li‐Tzong Chen's work include Pancreatic and Hepatic Oncology Research (76 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers) and Gastric Cancer Management and Outcomes (43 papers). Li‐Tzong Chen is often cited by papers focused on Pancreatic and Hepatic Oncology Research (76 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers) and Gastric Cancer Management and Outcomes (43 papers). Li‐Tzong Chen collaborates with scholars based in Taiwan, United States and South Korea. Li‐Tzong Chen's co-authors include Yan‐Shen Shan, Ann‐Lii Cheng, Jeffrey S. Chang, Jang‐Yang Chang, Yoon‐Koo Kang, Kun‐Huei Yeh, Nai‐Jung Chiang, Wen‐Chun Hung, Chien‐Feng Li and Chiun Hsu and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Li‐Tzong Chen

287 papers receiving 7.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Yoon‐Koo Kang, Li‐Tzong Chen et al. profile →
Management of gastric cancer in Asia: resource-stratified guidelines

2013 384 citations Yan‐Shen Shan, Kun‐Huei Yeh et al. profile →
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

2022 159 citations Li‐Tzong Chen et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Li‐Tzong Chen	2.6k	2.4k	1.9k	1.8k	1.2k	296	7.3k
Mary P. Bronner	3.4k 1.3×	2.5k 1.1×	3.7k 2.0×	2.1k 1.1×	1.9k 1.6×	173	10.1k
Kun‐Huei Yeh	3.4k 1.3×	2.2k 0.9×	1.4k 0.7×	2.3k 1.3×	914 0.8×	258	6.7k
Scott M. Wilhelm	2.8k 1.1×	3.5k 1.5×	1.3k 0.7×	1.6k 0.9×	1.3k 1.1×	70	9.0k
Shoji Nakamori	4.4k 1.7×	3.6k 1.5×	2.7k 1.4×	1.9k 1.0×	2.0k 1.7×	276	10.1k
Hans Prenen	4.0k 1.5×	2.6k 1.1×	1.3k 0.7×	2.6k 1.4×	1.6k 1.3×	207	8.6k
Tsutomu Fujii	5.2k 2.0×	2.2k 0.9×	3.4k 1.8×	2.9k 1.6×	1.4k 1.2×	330	8.7k
Yasuhide Yamada	5.3k 2.0×	4.3k 1.8×	1.6k 0.8×	3.8k 2.1×	1.9k 1.6×	308	10.9k
Steven N. Hochwald	3.2k 1.2×	1.3k 0.6×	3.0k 1.6×	2.7k 1.4×	793 0.7×	210	7.4k
Mario Scartozzi	3.7k 1.4×	1.7k 0.7×	834 0.4×	2.1k 1.1×	1.5k 1.2×	343	6.4k
Kazuo Shirouzu	4.2k 1.6×	2.0k 0.9×	3.8k 2.0×	2.9k 1.6×	786 0.7×	484	8.8k

Countries citing papers authored by Li‐Tzong Chen

Since Specialization

Citations

This map shows the geographic impact of Li‐Tzong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li‐Tzong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li‐Tzong Chen more than expected).

Fields of papers citing papers by Li‐Tzong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li‐Tzong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li‐Tzong Chen. The network helps show where Li‐Tzong Chen may publish in the future.

Co-authorship network of co-authors of Li‐Tzong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Li‐Tzong Chen. A scholar is included among the top collaborators of Li‐Tzong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li‐Tzong Chen. Li‐Tzong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tang, Lin‐Quan, Sai-Lan Liu, Muh‐Hwa Yang, et al.. (2025). GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study. Clinical Cancer Research. 31(16). 3424–3432.

Kuo, Tzu‐Lei, Ya‐Chin Hou, Yan‐Shen Shan, Li‐Tzong Chen, & Wen‐Chun Hung. (2025). Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. Clinical and Translational Medicine. 15(7). e70394–e70394.

Wang, Yeng‐Tseng, et al.. (2024). RNF43 Inactivation Enhances the B‐RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells. Advanced Science. 11(12). e2304820–e2304820. 4 indexed citations

Su, Yung‐Yeh, Nai‐Jung Chiang, Yi‐Hsin Yang, et al.. (2023). Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Cancers. 15(4). 1008–1008. 5 indexed citations

Luo, Chi‐Wen, Shih‐Feng Cho, Yi‐Chang Liu, et al.. (2023). Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. Biomedicines. 11(3). 691–691. 2 indexed citations

Wang, Hui‐Ching, Shih‐Feng Cho, Chun‐Chieh Wu, et al.. (2023). The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort. Biomedicines. 11(12). 3113–3113. 1 indexed citations

Kuo, Sung‐Hsin, Kun‐Huei Yeh, Chung‐Wu Lin, et al.. (2022). Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers. 14(4). 1005–1005. 13 indexed citations

Tan, Kien Thiam, Li‐Yuan Bai, Chin‐Fu Hsiao, et al.. (2022). Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical Cancer Research. 28(19). 4248–4257. 13 indexed citations

Kang, Yoon‐Koo, Martin Reck, Paul Nghiem, et al.. (2022). Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. Journal for ImmunoTherapy of Cancer. 10(4). e004273–e004273. 10 indexed citations

10.

Chen, Li‐Tzong, et al.. (2022). Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness. Cancer Science. 113(5). 1601–1612. 13 indexed citations

11.

Chiang, Nai‐Jung, Li‐Tzong Chen, Yan‐Shen Shan, Chun‐Nan Yeh, & Ming‐Huang Chen. (2021). Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules. 11(1). 97–97. 5 indexed citations

12.

Tsai, Chia‐Hua, et al.. (2021). An Adjustable Dark-Field Acoustic-Resolution Photoacoustic Imaging System with Fiber Bundle-Based Illumination. Biosensors. 11(8). 262–262. 5 indexed citations

13.

Lin, Yan‐Ren, Chia‐Hua Tsai, Tzong-Rong Ger, et al.. (2021). Assessment of Brain Functional Activity Using a Miniaturized Head-Mounted Scanning Photoacoustic Imaging System in Awake and Freely Moving Rats. Biosensors. 11(11). 429–429. 4 indexed citations

14.

Kuo, Sung‐Hsin, Ming‐Shiang Wu, Kun‐Huei Yeh, et al.. (2019). Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers. 11(4). 547–547. 32 indexed citations

15.

Li, Chien‐Feng, Fu‐Min Fang, Yen‐Yang Chen, et al.. (2017). Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib. Clinical Cancer Research. 23(16). 4908–4918. 33 indexed citations

16.

Kuo, Sung‐Hsin, Kun‐Huei Yeh, Ming‐Shiang Wu, et al.. (2017). First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Scientific Reports. 7(1). 19 indexed citations

17.

Chen, Li‐Tzong, Chiung-Tong Chen, Tsai‐Yun Chen, et al.. (2016). BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT –Driven Myeloid Leukemia. Molecular Cancer Therapeutics. 15(10). 2323–2333. 10 indexed citations

18.

Kuo, Sung‐Hsin, Li‐Tzong Chen, Chung‐Wu Lin, et al.. (2016). Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood. 129(2). 188–198. 20 indexed citations

19.

Huang, Hsuan-Ying, Wen-Ren Wu, Yu-Hui Wang, et al.. (2013). ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance. Clinical Cancer Research. 19(11). 2861–2872. 118 indexed citations

20.

Kuo, Sung‐Hsin, Kun‐Huei Yeh, Ming‐Shiang Wu, et al.. (2012). Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas. Blood. 119(21). 4838–4844. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact